Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist

European Journal of Clinical Investigation

Volumn 32, Issue 12, 2002, Pages 949-955

  Mastalerz, L ^a   Nizankowska, E ^a   Sanak, M ^a   Mejza, F ^a   Pierzchalska, M ^a   Bazan Socha, S ^a   Bestynska Krypel, A ^a   Cmiel, A ^b   Szczeklik, Andrzej ^a,c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b AGH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Poland)

^c NONE   (Poland)

Author keywords

Aspirin induced asthma; Cysteinyl leukotrienes; Montelukast

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL; INTERLEUKIN 5; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE;

ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; EXPIRATORY FLOW RATE; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOM; TREATMENT OUTCOME;

ACETATES; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA; EOSINOPHILS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE C4; LUNG; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; QUINOLINES; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC;

EID: 0036906640     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.01088.x     Document Type: Article

References (29)

1. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science 1998;281:1820-2.
2. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Nat Acad Sci 1995;92:12260-4.
3. Barnes NC. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med 2000;161:573-6.
4. 1 receptor. Nature 1999;399:779-83.
5. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000;275:30531-6.
6. Szczeklik A, Nizankowska E, Sanak M, Mastalerz L, Bazan-Socha S. Leukotrienes and antileukotriene drugs in bronchial asthma with special reference to aspirin intolerance. Eur Respir Rev 2000;10:280-2.
7. Szczeklik A, Stevenson DD. Aspirin-induced asthma: Advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5-13.
8. 4 in humans. Clin Exp Allergy 1995;25:467-79.
9. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin sensitive asthmatics. Am J Respir Crit Care Med 1996;154:1608-14.
10. Sanak M, Sampson AP. Biosynthesis of cysteinyl-leukotrienes in aspirin-intolerant asthma. Clin Exp Allergy 1999;29:306-13.
11. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-46.
12. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-60.
13. Laing IA, Goldblatt J, Eber E, Hayden CM, Rye PJ, Gibson NA et al. A polymorphism of the CC16 gene is associated with an increased risk of asthma. J Med Genet 1998;35:463-7.
14. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997;10:646-51.
15. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832-8.
16. Cartwright GE. Diagnostic Laboratory Hematology, 4th Edn. New York: Grune Stratton;1968.pp. 48-50.
17. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C (4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000;23:290-6.
18. Pierzchalska M, Mastalerz L, Sanak M, Zazula M, Szczeklik A. A moderate and unspecific release of cysteinyl leukotrienes by aspirin from peripheral blood leukocytes precludes its value for aspirin sensitivity testing in asthma. Clin Exp Allergy 2000;30:1785-91.
19. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol 1998;102:50-6.
20. Holgate ST, Sampson AP. Antileukotriene therapy. Future directions. Am J Respir Crit Care Med 2000;161:147-53.
21. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-7.
22. Dahlén B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998;157:1187-94.
23. Dahlen SE, Malmstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
24. Diamant Z, Grootendorst DC, Veselic-Charvat M, Timmers MC, De Smet M, Leff JA et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exper Allergy 1999;29:42-51.
25. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX et al. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J 1999;14:12-8.
26. Tohda Y, Nakahara H, Kubo H, Haraguchi R, Fukuoka M, Nakajima S. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999;29:1532-6.
27. Kowalski MI, Grzegorczyk J, Pawliczak R. Decreased apoptosis in nasal polyps from patients with asa-sensitive rhinosinusitis/asthma (ASRSA). Allergy Clin Immunol 1999;1:247.
28. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW et al. Variant LTC (4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000;55:28-31.
29. 4 synthase genetic polymorphism directs urinary cysteine-leukotriene response to aspirin challenge in asthma. Allergy 1998;53:61.